ACST News and Press, Acasti Pharma Inc. From 11/19/19

Oppenheimer initiates Amarin (NASDAQ: AMRN ) with an Underperform rating and $7 price target, suggesting a  whopping 70% downside  from this afternoon's close. More news on: Amarin Corporation plc, Acasti Pharma Inc., Healthcare stocks news, Stocks on the move, Quick stock ideas,...

November 19, 2019 Palm Beach, FL –November 19, 2019 – A lot of cancer research is dealing with shrinking brain tumors and opening the door for targeted cancer therapies to work without damaging the surrounding tissue. The success rate for cancer therapies has been limite...

Acasti Pharma (NASDAQ: ACST ,TSXV:ACST) kickstarted the week by releasing preliminary data on Monday (November 18) from a preclinical mouse study evaluating its hypertriglyceridemia (HTG) drug CaPre as a potential treatment for type 2 diabetes.  CaPre demonstrated an increase in insul...

Acasti Pharma (NASDAQ: ACST ) resume with Buy rating and $8 (292% upside) price target at B. Riley FBR. Shares up  5%  premarket. More news on: Acasti Pharma Inc., Champions Oncology, Inc., DexCom, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Data from a new preclinical mouse study suggests a unique mechanism of CaPre compared to metformin and icosapent ethyl (VASCEPA ® ) in a diet-induced obesity animal model   Preliminary, statistically significant findings show that CaPre may promote insulin secretion, and...

Plus Therapeutics (NASDAQ: PSTV ) +30%  after Q3 results . More news on: Plus Therapeutics, Inc., Farfetch Limited, RadNet, Inc., Stocks on the move, Read more ...

Acasti Pharma (NASDAQ: ACST ) and Matinas BioPharma Holdings (NYSEMKT: MTNB ) are jumping after hours following Amarin's FDA panel win to expand the label for its heart drug Vascepa. More news on: Acasti Pharma Inc., Matinas BioPharma Holdings, Inc., Healthcare stocks news, Stocks on the...

Start Time: 13:00 End Time: 13:40 Acasti Pharma Inc. (ACST) Q2 2020 Earnings Conference Call November 13, 2019, 13:00 PM ET Company Participants Jan D’Alvise - President and CEO Jean-François Boily - VP, Finance Pierre Lemieux - Co-Founder, COO and CSO Brian Gro...

Acasti Pharma ( ACST ) Q2 results (C$): Revenues: 0; R&D Expense: 5.2M (-42.9%); SG&A: 3.4M (+161.5%); Net loss: (28.3M) (-24.7%); loss/share: (0.34) (+45.2%); Quick Assets: 25.8M (-25.0%); CF Ops: (17.5M) (-43.4%). More news on: Acasti Pharma Inc., Healthcare stocks news, Earnin...

November 13, 2019 Palm Beach, FL –November 13, 2019 – For decades researchers have been trying to find newer and more effective ways to fight cancer cells. Today much research is focused on attacking the cancerous cells growth. The reasoning is that denying these cells e...